研究紹介
発表論文(国際)
- 2023年
- 2022年
2022-01.
Ebina K, Abe T, Hotta K, Higuchi M, Furumido J, Iwahara N, Kon M, Miyaji K, Shibuya S, Lingbo Y, Komizunai S, Kurashima Y, Kikuchi H, Matsumoto R, Osawa T, Murai S, Tsujita T, Sase K, Chen X, Konno A, Shinohara N. Automatic assessment of laparoscopic surgical skill competence based on motion metrics. PLoS One. 2022;17(11):e0277105. [5Y-IF:3.8]
2022-02.
Ebina K, Abe T, Hotta K, Higuchi M, Furumido J, Iwahara N, Kon M, Miyaji K, Shibuya S, Lingbo Y, Komizunai S, Kurashima Y, Kikuchi H, Matsumoto R, Osawa T, Murai S, Tsujita T, Sase K, Chen X, Konno A, Shinohara N. Objective evaluation of laparoscopic surgical skills in wet lab training based on motion analysis and machine learning. Langenbecks Arch Surg. 2022;407(5):2123-32. [5Y-IF:2.7]
2022-03.
Hayashi A, Okamoto T, Nio-Kobayashi J, Iwahara N, Suzuki R, Ueda Y, Takahashi T, Yasuyuki S, Iwanaga T, Hotta K. CD44 as a pathological marker for the early detection of calcineurin inhibitor-induced nephrotoxicity post kidney transplantation. Biomed Res. 2022;43(5):181-6. [5Y-IF:1.8]
2022-04.
Hayashi A, Yamamoto I, Kawabe M, Kobayashi A, Ito M, Hotta K, Shinohara N, Tasaki T, Yokoo T, Iwami D. CASE REPORT: Serial Cases of False-Positive Flow-Cytometry T Cell Crossmatch Associated With Anti-Blood Type Antibodies in Patients Undergoing ABO-Incompatible Kidney Transplantation. Front Immunol. 2022;13:862652. [5Y-IF:8]
2022-05.
Hirose T, Hotta K, Harada H, Tanabe T, Sasaki H, Shinohara N. Vesicoureteral reflux treatment following kidney transplantation potentially prevents graft function deterioration and allows long-term graft survival. Int J Urol. 2022;29(7):699-706. [5Y-IF:2.9]
2022-06.
Iwasa T, Noguchi H, Aoki H, Tamura K, Maeda T, Takeda A, Uchishiba M, Arakaki R, Minato S, Kamada S, Yamamoto S, Imaizumi J, Kagawa T, Yoshida A, Fukui R, Daizumoto K, Kon M, Shinohara N, Yoshida K, Yamamoto Y. Effects of undernutrition and low energy availability on reproductive functions and their underlying neuroendocrine mechanisms. Endocr J. 2022;69(12):1363-72. [5Y-IF: 2.3]
2022-07.
Kato T, Matsubara N, Shiota M, Eto M, Osawa T, Abe T, Shinohara N, Yasumizu Y, Tanaka N, Oya M, Nishimoto K, Hayashi T, Nakayama M, Kojima T, Namikawa K, Fujisawa T, Okano S, Hida E, Nakamura Y, Bando H, Yoshino T, Nonomura N. IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation. BMC Cancer. 2022;22(1):1292. [5Y-IF: 4.3]
2022-08.
Kikuchi H, Osawa T, Abe T, Matsumoto R, Maruyama S, Murai S, Shinohara N. Quality improvement in managing patients with non-muscle-invasive bladder cancer by introducing a surgical checklist for transurethral resection of bladder tumor. PLoS One. 2022;17(10):e0276816. [5Y-IF:3.8]
2022-09.
Kitta T, Chiba H, Kon M, Higuchi M, Kusakabe N, Ouchi M, Togo M, Abe-Takahashi Y, Tsukiyama M, Shinohara N. Urodynamic evaluation of the efficacy of vibegron, a new β3-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder. J Pediatr Urol. 2022;18(5):563-9. [5Y-IF:2]
2022-10.
Narita S, Terada N, Nomura K, Sakamoto S, Hatakeyama S, Kato T, Matsui Y, Inokuchi J, Yokomizo A, Tabata KI, Shiota M, Kimura T, Kojima T, Inoue T, Mizowaki T, Sugimoto M, Kitamura H, Kamoto T, Nishiyama H, Habuchi T. Cancer-specific and net overall survival in older patients with de novo metastatic prostate cancer initially treated with androgen deprivation therapy. Int J Urol. 2022;29(10):1147-54. [5Y-IF:2.9]
2022-11.
Nezu K, Yamashita S, Kakimoto K, Uemura M, Kishida T, Kawai K, Nakamura T, Goto T, Osawa T, Nishimura K, Nonomura N, Negoro H, Shiraishi T, Ukimura O, Ogawa O, Shinohara N, Suzukamo Y, Ito A, Arai Y. Association of financial toxicity with quality of life in testicular cancer survivors. Int J Urol. 2022;29(12):1526-34. [5Y-IF:2.9]
2022-12.
Rosales IA, Mahowald GK, Tomaszewski K, Hotta K, Iwahara N, Otsuka T, Tsuji T, Takada Y, Acheampong E, Araujo-Medina M, Bruce A, Rios A, Cosimi AB, Elias N, Kawai T, Gilligan H, Safa K, Riella LV, Tolkoff-Rubin NE, Williams WW, Jr., Smith RN, Colvin RB. Banff Human Organ Transplant Transcripts Correlate with Renal Allograft Pathology and Outcome: Importance of Capillaritis and Subpathologic Rejection. J Am Soc Nephrol. 2022;33(12):2306-19. [5Y-IF:12.5]
2022-13.
Sato M, Osawa T, Abe T, Honda M, Higuchi M, Yamada S, Furumido J, Kikuchi H, Matsumoto R, Sato Y, Sasaki Y, Harabayashi T, Maruyama S, Takada N, Minami K, Tanaka H, Morita K, Kashiwagi A, Murai S, Ito YM, Ogasawara K, Shinohara N. Validation of the Japanese version of the Body Image Scale for bladder cancer Minami K, Tanaka H, Morita K, Kashiwagi A, Murai S, Ito YM, Ogasawara K, Shinohara patients. Sci Rep. 2022;12(1):21544. [5Y-IF:4.9]
2022-14.
Tachibana A, Yamamoto Y, Noguchi H, Takeda A, Tamura K, Aoki H, Minato S, Uchishiba M, Yamamoto S, Kamada S, Yoshida A, Kinouchi R, Yoshida K, Iwasa T. Changes in Serum Oxytocin Levels under Physiological and Supraphysiological Gonadal Steroid Hormone Conditions in Women of Reproductive Age: A Preliminary Study. Changes in Serum Oxytocin Levels under Physiological and Supraphysiological Gonadal Nutrients. 2022;14(24). [5Y-IF:N/A]
2022-15.
Yamada R, Morikawa K, Hotta K, Iwami D, Tanabe T, Murai S, Shinohara N, Yoshida S, Hosoda S, Kubo A, Tokuchi Y, Kitagataya T, Kimura M, Yamamoto K, Nakai M, Sho T, Suda G, Natsuizaka M, Ogawa K, Sakamoto N. Incidence of post-transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection. J Viral Hepat. 2022;29(11):976-85. [5Y-IF:2.6]
2023-01.
Abe T, Yamada S, Kikuchi H, Sazawa A, Katano H, Suzuki H, Takeuchi I, Minami K, Morita K, Tsuchiya K, Takada N, Maru S, Sato S, Yamashita T, Mochizuki T, Akino T, Sasaki Y, Shinno Y, Murahashi N, Kawazu T, Furumido J, Miyata H, Matsumoto R, Osawa T, Murai S, Shinohara N. Impact of postoperative complications on long-term survival in bladder cancer patients. Jpn J Clin Oncol. 2023;53(10):966-76. Matsumoto R, Osawa T, Murai S, Shinohara N. Impact of postoperative complications [5Y-IF: 2.6]
2023-02.
Anand RP, Layer JV, Heja D, Hirose T, Lassiter G, Firl DJ, Paragas VB, Akkad A, Chhangawala S, Colvin RB, Ernst RJ, Esch N, Getchell K, Griffin AK, Guo X, Hall KC, Hamilton P, Kalekar LA, Kan Y, Karadagi A, Li F, Low SC, Matheson R, Nehring C, Otsuka R, Pandelakis M, Policastro RA, Pols R, Queiroz L, Rosales IA, Serkin WT, Stiede K, Tomosugi T, Xue Y, Zentner GE, Angeles-Albores D, Chris Chao J, Crabtree JN, Harken S, Hinkle N, Lemos T, Li M, Pantano L, Stevens D, Subedar OD, Tan X, Yin S, Anwar IJ, Aufhauser D, Capuano S, Kaufman DB, Knechtle SJ, Kwun J, Shanmuganayagam D, Markmann JF, Church GM, Curtis M, Kawai T, Youd ME, Qin W. Design and testing of a humanized porcine donor for xenotransplantation. Nature. 2023;622(7982):393-401. [5Y-IF: 60.9]
2023-03.
Blas L, Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M. Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP- RCC study. Int J Urol. 2023;30(9):788-96. [5Y-IF: 2.9]
2023-04.
Chandler C, Burnett H, Schaible K, Senthil V, Kato M, Miura Y, Osawa T, Uemura H, Kuwabara H. Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan. J Med Econ. 2023;26(1):1009-18. [5Y-IF: 2.3]
2023-05.
Firl DJ, Lassiter G, , Policastro R, D'Attilio A, Markmann JF, Kawai T, Hall KC. Clinical and molecular correlation defines activity of physiological pathways in life-sustaining kidney xenotransplantation. Nat Commun. 2023;14(1):3022. [5Y-IF: 17]
2023-06.
Fujiyama N, Tasaki M, Harada H, Tsutahara K, Matsumoto A, Kamijo Y, Toyoda M, Iwami D, Inui M, Shirakawa H, Sugimura J, Saito M, Hotta K, Okumi M, Saito K, Watarai Y, Hidaka Y, Ohtani K, Inoue N, Wakamiya N, Habuchi T, Satoh S. Immunological risk and complement genetic evaluations in early onset de novo thrombotic microangiopathy after living donor kidney transplantation: A Japanese multicenter registry. Clin Exp Nephrol. 2023;27(12):1010-20. [5Y-IF: 2.4]
2023-07.
Furumido J, Maishi N, Yanagawa-Matsuda A, Kikuchi H, Matsumoto R, Osawa T, Abe T, Matsuno Y, Shinohara N, Hida Y, Hida K. Stroma biglycan expression can be a prognostic factor in prostate cancers. Int J Urol. 2023;30(2):147-54. [5Y-IF: 2.9]
2023-08.
Hagio K, Kikuchi J, Takada K, Tanabe H, Sugiyama M, Ohhara Y, Amano T, Yuki S, Komatsu Y, Osawa T, Hatanaka KC, Hatanaka Y, Mitamura T, Yabe I, Matsuno Y, Manabe A, Sakurai A, Ishiguro A, Takahashi M, Yokouchi H, Naruse H, Mizukami Y, Dosaka-Akita H, Kinoshita I. Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers. Cancer Sci. 2023;114(8):3385- 95. [5Y-IF: 6]
2023-09.
Harada H, Fukuzawa N, Abe T, Imamura R, Masaki N, Fujiyama N, Sato S, Hatakeyama S, Nishimura K, Kishikawa H, Iwami D, Hotta K, Miura M, Ide K, Nakamura M, Kosoku A, Uchida J, Murakami T, Tsuji T. Development and nationwide validation of kidney graft injury markers using urinary exosomes and microvesicles (complete English translation of the Japanese version). BMC Nephrol. 2023;24(1):158. [5Y-IF: 2.8]
2023-10.
Iesaka H, Kameda H, Miya A, Nomoto H, Cho KY, Nakamura A, Abe T, Shinohara N, Atsumi T. Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report. Medicine (Baltimore). 2023;102(51):e36664. [5Y-IF: 1.9]
2023-11.
Imaizumi J, Kamada S, Taniguchi M, Sugimoto T, Maeda T, Arakaki R, Yamamoto S, Shirakawa A, Mineda A, Yoshida A, Iwasa T, Kaji T. Developmental Changes in Hypothalamic and Serum Oxytocin Levels in Prenatally Normally Nourished and Undernourished Rats. Nutrients. 2023;15(12). [5Y-IF: 6.6]
2023-12.
Iwahara N, Hotta K, Hirose T, Shinohara N. Long-Term Results in Recipients of Late Conversion to a Calcineurin Inhibitor-Free Regimen with Everolimus After Kidney Transplantation. Transplant Proc. 2023;55(4):803-8. [5Y-IF: 0.9]
2023-13.
Iwahara N, Hotta K, Iwami D, Tanabe T, Tanaka Y, Ito YM, Otsuka T, Murai S, Takada Y, Higuchi H, Sasaki H, Hirose T, Harada H, Shinohara N. Analysis of T-cell alloantigen response via a direct pathway in kidney transplant recipients with donor- specific antibodies. Front Immunol. 2023;14:1164794. [5Y-IF: 8]
2023-14.
Kato T, Wang C, Masumori N, Yamasaki T, Matsumoto H, Baba M, Ito K, Kimura T, Kitamura H, Takahashi M, Hongo F, Hasine K, Eto M, Ikeda JI, Nonomura N, Shinohara N. T1a Renal Cell Carcinoma With Metastasis: Japanese Society of Renal Cancer Retrospective Multi-institute Results. Anticancer Res. 2023;43(9):4061-5. [5Y-IF: 2.2]
2023-15.
Kirisawa T, Shiota M, Kimura T, Edamura K, Miyake M, Morizane S, Yoshino T, Matsukawa A, Matsumoto R, Kasahara T, Nishiyama N, Eto M, Kitamura H, Nakamura E, Matsui Y. Comparison of therapeutic features and oncologic outcome in patients with pN1 prostate cancer among robot-assisted, laparoscopic, or open radical prostatectomy. Int J Clin Oncol. 2023;28(2):306-13. [5Y-IF: 3.3]
2023-16.
Kitta T, Kanno-Kakibuchi Y, Chiba H, Higuchi M, Ouchi M, Togo M, Abe-Takahashi Y, Tsukiyama M, Shinohara N. Episodes of Febrile Urinary Tract Infections Occur More Often in the Winter in Patients with Spina Bifida. Urol Res Pract. 2023;49(3):211-5. [5Y-IF: 3.3]
2023-17.
Koyama J, Yamashita S, Kakimoto K, Uemura M, Kishida T, Kawai K, Nakamura T, Goto T, Osawa T, Nishimura K, Nonomura N, Nishiyama H, Shiraishi T, Ukimura O, Ogawa O, Shinohara N, Suzukamo Y, Ito A, Arai Y. Sexual function using the EORTC QLQ-TC26 in testicular cancer survivors: A multi-institutional, cross-sectional study. Int J Urol. 2023;30(11):1044-50. [5Y-IF: 2.9]
2023-18.
Lassiter G, Otsuka R, Hirose T, Rosales I, Karadagi A, Tomosugi T, Dehnadi A, Lee H, Colvin RB, Baardsnes J, Moraitis A, Smith EE, Ali Z, Berhe P, Mulder A, Meibohm B, Daugherty B, Fogarty S, Pierson RN, Lederman S, Kawai T. TNX-1500, a crystallizable fragment-modified anti-CD154 antibody, prolongs nonhuman primate renal allograft survival. Am J Transplant. 2023;23(8):1171-81. [5Y-IF: 7.4]
2023-19.
Matsumoto R. Editorial Comment to "A national questionnaire survey of Japanese urologists on active surveillance for low- and intermediate-risk prostate cancer". Int J Urol. 2023;30(3):297. [5Y-IF: 2.9]
2023-20.
Minami K, Osawa T, Kojima T, Hara T, Eto M, Takeuchi A, Nakai Y, Ueda K, Ozawa M, Uemura M, Ohba K, Tamura K, Shindo T, Nakagomi H, Takahashi A, Anai S, Yokomizo A, Morizane S, Kimura T, Shimazui T, Miyauchi Y, Mitsuzuka K, Hara H, Yoshimura K, Shiina H, Ito YM, Murai S, Nishiyama H, Shinohara N, Kitamura H. Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment. Urol Oncol. 2023;41(11):458.e9-.e19. [5Y-IF: 2.8]
2023-21.
Morimoto M, Maishi N, Tsumita T, Alam MT, Kikuchi H, Hida Y, Yoshioka Y, Ochiya T, Annan DA, Takeda R, Kitagawa Y, Hida K. miR-1246 in tumor extracellular vesicles promotes metastasis via increased tumor cell adhesion and endothelial cell barrier destruction. Front Oncol. 2023;13:973871. [5Y-IF: 5.2]
2023-22.
Munekata Y, Yamamoto S, Kato S, Kitagawa Y, Enda K, Okazaki N, Tanikawa S, Tanei ZI, Ikebe Y, Osawa T, Takamiya S, Ujiie H, Onozawa M, Hirano S, Fujimura M, Tanaka S. Fatal case of subdural empyema caused by Campylobacter rectus and Slackia exigua. Autops Case Rep. 2023;13:e2023433. [5Y-IF: N/A]
2023-23.
Nakaigawa N, Tomita Y, Tamada S, Tatsugami K, Osawa T, Oya M, Kanayama H, Miura Y, Sassa N, Nishimura K, Nozawa M, Masumori N, Miyoshi Y, Kuroda S, Kimura A. Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma. Int J Clin Oncol. 2023;28(3):416-26. [5Y-IF: 3.3]
2023-24.
Nishioka N, Fujima N, Tsuneta S, Yoneyama M, Matsumoto R, Abe T, Kimura R, Sakamoto K, Kato F, Kudo K. Clinical utility of single-shot echo-planar diffusion-weighted imaging using L1-regularized iterative sensitivity encoding in prostate MRI. Medicine (Baltimore). 2023;102(17):e33639. [5Y-IF: 1.9]
2023-25.
Nishiyama H, Yonese J, Kawahara T, Matsumoto R, Miyake H, Matsubara N, Uemura H, Eto M, Azuma H, Obara W, Terai A, Fukasawa S, Suekane S. TAS0313 Plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor-Naïve Locally Advanced or Metastatic Urothelial Carcinoma. Mol Cancer Ther. 2023. [5Y-IF: 6.3]
2023-26.
Nonoyama S, Hotta K, Iwahara N, Tanabe T, Hirose T, Harada S, Sugita J, Nakazawa D, Shigematsu A, Otsuka T, Shinohara N. Use of Mixed Lymphocyte Reaction Assay to Evaluate Immune Tolerance before Kidney Transplantation with an Immunosuppression-Free Protocol following Hematopoietic Stem Cell Transplantation from the Same Donor. Nephron. 2023;147(10):621-6. [5Y-IF: 2.9]
2023-27.
Numakura K, Miyake M, Kobayashi M, Muto Y, Sekine Y, Nishimura N, Iida K, Shiga M, Morizane S, Yoneyama T, Matsumura Y, Abe T, Yamada T, Matsumoto K, Inokuchi J, Nishiyama N, Taoka R, Kobayashi T, Kojima T, Kitamura H, Nishiyama H, Fujimoto K, Habuchi T. Subsequent Upper Urinary Tract Carcinoma Related to Worse Survival in Patients Treated with BCG. Cancers (Basel). 2023;15(7). [5Y-IF: 5.6]
2023-28.
Osawa T, Fujii Y, Kimura G, Kitamura H, Nagashima Y, Iizumi S, Osaka T, Tsubouchi R, Shinohara N. Electronic patient-reported outcome (e-PRO) monitoring for adverse event management during cabozantinib treatment in patients with advanced renal cell carcinoma: protocol for a three-arm, randomised, multicentre phase II trial (e-PRO vs paper-PRO or usual care). BMJ Open. 2023;13(7):e070275. [5Y-IF: 3.3]
2023-29.
Osawa T, Oya M, Okanishi T, Kuwatsuru R, Kawano H, Tomita Y, Niida Y, Nonomura N, Hatano T, Fujii Y, Mizuguchi M, Shinohara N. Clinical Practice Guidelines for tuberous sclerosis complex-associated renal angiomyolipoma by the Japanese Urological Association: Summary of the update. Int J Urol. 2023;30(10):808-17. [5Y-IF: 2.9]
2023-30.
Otsuka T, Tanabe T, Hotta K, Iwasaki S, Tsuji T, Takahashi A, Takakuwa E, Shinohara N, Matsuno Y. Exacerbation of Intimal Fibrosis and Endarteritis in a Kidney Transplant Recipient with Chronic Active Antibody-Mediated Rejection and COVID-19: A Case Report. Nephron. 2023;147 Suppl 1:41-5. [5Y-IF: 2.9]
2023-31.
Pal SK, Albiges L, Tomczak P, Suárez C, Voss MH, de Velasco G, Chahoud J, Mochalova A, Procopio G, Mahammedi H, Zengerling F, Kim C, Osawa T, Angel M, Gupta S, Khan O, Bergthold G, Liu B, Kalaitzidou M, Huseni M, Scheffold C, Powles T, Choueiri TK. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2023;402(10397):185-95. [5Y-IF: 118.1]
2023-32.
Sakka S, Kandori S, Kawai K, Kojima T, Nitta S, Chihara I, Nagumo Y, Kawahara T, Mathis BJ, Ishihara M, Shinohara N, Kishida T, Ukimura O, Nishimura K, Kobayashi Y, Nishiyama H. Plasma circulating tumor DNA profiling in patients with chemo-refractory germ cell tumors. Int J Urol. 2023;30(5):456-62. [5Y-IF: 2.9]
2023-33.
Sasaki H, Hirose T, Oura T, Otsuka R, Rosales I, Ma D, Lassiter G, Karadagi A, Tomosugi T, Dehnadi A, Matsunami M, Raju Paul S, Reeves PM, Hanekamp I, Schwartz S, Colvin RB, Lee H, Spitzer TR, Cosimi AB, Cippà PE, Fehr T, Kawai T. Selective Bcl-2 inhibition promotes hematopoietic chimerism and allograft tolerance without myelosuppression in nonhuman primates. Sci Transl Med. 2023;15(690):eadd5318. [5Y-IF: 19]
2023-34.
Sasaki H, Tanabe T, Tsuji T, Hotta K. Mechanism and treatment for chronic antibody-mediated rejection in kidney transplant recipients. Int J Urol. 2023;30(8):624-33. [5Y-IF: 2.9]
2023-35.
Sazuka T, Matsushita Y, Sato H, Osawa T, Hinata N, Hatakeyama S, Numakura K, Ueda K, Kimura T, Takahashi M, Tanaka H, Kawasaki Y, Kurahashi T, Kato T, Fujita K, Miyake M, Kojima T, Kitamura H, Miyake H, Ichikawa T. Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective study. Sci Rep. 2023;13(1):20629. [5Y-IF: 4.9]
2023-36.
Shinohara N. This Issue 30-5. Int J Urol. 2023 May;30(5):421. [5Y-IF: 2.9]
2023-37.
Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M. Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial. Cancer Immunol Immunother. 2023;72(6):1903-15. [5Y-IF: 6.1]
2023-38.
Smith RN, Rosales IA, Tomaszewski KT, Mahowald GT, Araujo-Medina M, Acheampong E, Bruce A, Rios A, Otsuka T, Tsuji T, Hotta K, Colvin R. Utility of Banff Human Organ Transplant Gene Panel in Human Kidney Transplant Biopsies. Transplantation. 2023;107(5):1188-99. [5Y-IF: 5.1]
2023-39.
Suto A, Yano Y, Yamamoto Y, Noguchi H, Takeda A, Yamamoto S, Kagawa T, Yoshida K, Hinokio K, Kuwahara A, Yasui T, Iwasa T. Effects of activation with a Ca ionophore and roscovitine on the development of human oocytes that failed to fertilize after ICSI. J Med Invest. 2023;70(3.4):321-4. [5Y-IF: N/A]
2023-40.
Suzuki M, Miyaji K, Matoba K, Abe T, Nakamaru Y, Watanabe R, Suzuki T, Nakazono A, Konno A, Hinder D, Psaltis AJ, Wormald PJ, Homma A. Mental workload during endoscopic sinus surgery is associated with surgeons' skill levels. Front Med (Lausanne). 2023;10:1090743. [5Y-IF: 4.2]
2023-41.
Takada Y, Hotta K, Moriya K, Sasaki H, Takamoto D, Higuchi H, Tanabe T, Minami K, Iwasaki S, Tsuji T, Tanaka H. A Case of Kidney Transplantation from a Deceased Donor with Acute Kidney Injury due to Rhabdomyolysis. Nephron. 2023;147 Suppl 1:101-5. [5Y-IF: 2.9]
2023-42.
Takenaka J, Watanabe S, Abe T, Hirata K, Uchiyama Y, Kimura R, Shinohara N, Kudo K. Prognostic value of [(18)F]FDG-PET prior to [(131)I]MIBG treatment for pheochromocytoma and paraganglioma (PPGL). Ann Nucl Med. 2023;37(1):10-7. [5Y-IF: 2.5]
2023-43.
Takenaka J, Watanabe S, Abe T, Tsuchikawa T, Takeuchi S, Hirata K, Kimura R, Wakabayashi N, Shinohara N, Kudo K. Predictive factors of early FDG-PET response to [131I] MIBG treatment for unresectable or metastatic pheochromocytomas and paragangliomas (PPGLs). Neuroendocrinology. 2023. [5Y-IF: 5]
2023-44.
Togo M, Kitta T, Chiba H, Higuchi M, Kusakabe N, Ouchi M, Abe-Takahashi Y, Kakizaki H, Shinohara N. Effects of a new selective β(3) -adrenoceptor agonist, vibegron, on bladder and urethral function in a rat model of Parkinson's disease. Low Urin Tract Symptoms. 2023;15(6):265-70. [5Y-IF: N/A]
2023-45.
Tohi Y, Ishikawa R, Kato T, Miyakawa J, Matsumoto R, Mori K, Mitsuzuka K, Inokuchi J, Matsumura M, Shiga K, Naito H, Kohjimoto Y, Kawamura N, Inoue M, Akamatsu S, Terada N, Miyazawa Y, Narita S, Haba R, Sugimoto M. Increasing age predicts adverse pathology including intraductal carcinoma of the prostate and cribriform patterns in deferred radical prostatectomy after upfront active surveillance for Gleason grade group 1 prostate cancer: analysis of prospective observational study cohort. Jpn J Clin Oncol. 2023;53(10):984-90. [5Y-IF: 2.6]
2023-46.
Tohi Y, Ishikawa R, Kato T, Miyakawa J, Matsumoto R, Mori K, Mitsuzuka K, Inokuchi J, Matsumura M, Shiga K, Naito H, Kohjimoto Y, Kawamura N, Inoue M, Kinoshita H, Hashimoto K, Goto K, Haba R, Kakehi Y, Sugimoto M. Clinical outcomes of intraductal carcinoma or cribriform in radical prostatectomy specimens of men opting for active surveillance: data from the PRIAS-JAPAN study. Int J Clin Oncol. 2023;28(2):299-305. [5Y-IF: 3.3]
2023-47.
Tsuzuki T, Ohe C, Osawa T, Yasuda Y, Tanaka T, Anai S, Kimura G, Yamana K, Hatakeyama S, Yoshimoto T, Nakagawa Y, Fukuyama T, Matsubara N, Uemura H. Prognostic value of immune phenotype and PD-L1 status in recurrent or metastatic renal cell carcinoma: an exploratory analysis of the ARCHERY study. Pathology. 2023;55(1):31-9. [5Y-IF: 4.4]
2023-48.
Uemura H, Shinohara N, Tomita Y, Nonomura N, Yamada T, Yoshida A, Komoto A. The safety profile of nivolumab plus ipilimumab combination therapy in Japanese patients with renal cell carcinoma: results from post-marketing surveillance. Jpn J Clin Oncol. 2023;53(8):730-7. [5Y-IF: 2.9]
2023-49.
Yagi Y, Kubo Y, Hoshino K, Okada K, Hotta K, Shinohara N, Morimoto Y. Differences of cerebral oxygen saturation in dialysis patients: a comparison of three principals of near infrared spectroscopy. J Anesth. 2023;37(6):861-7. [5Y-IF: 2.5]
2023-50.
Yamada S, Miyata H, Isono M, Hori K, Yanagawa J, Murai A, Minowa T, Mizue Y, Sasaki K, Murata K, Tokita S, Nakatsugawa M, Iwabuchi S, Hashimoto S, Kubo T, Kanaseki T, Tsukahara T, Abe T, Shinohara N, Hirohashi Y, Torigoe T. Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma. Cancer Immunol Immunother. 2023;72(7):2057-65. [5Y-IF: 6.1]
2023-51.
Yamamoto S, Arakaki R, Noguchi H, Takeda A, Uchishiba M, Kamada S, Mineda A, Kon M, Kawakita T, Kinouchi R, Yamamoto Y, Yoshida K, Shinohara N, Iwasa T. New discoveries on the interaction between testosterone and oxytocin in male rats - Testosterone-mediated effects of oxytocin in the prevention of obesity. Physiol Behav. 2023;266:114199. [5Y-IF: 3.3]
2024-01.
Abe-Takahashi Y, Kitta T, Ouchi M, Chiba H, Higuchi M, Togo M, Kusakabe N, Kakizaki H, Shinohara N. Morphological examination of pelvic floor muscles in a rat model of vaginal delivery. BMC Pregnancy Childbirth. 2024;24(1):95. [5Y-IF: 3.8]
2024-02.
Hirose T, Hotta K, Osawa T, Yokota I, Inao T, Tanabe T, Iwahara N, Shinohara N. Longitudinal mortality risks and kidney functional outcomes in Japanese living kidney donors. Int J Urol. 2024. [5Y-IF: 2.9]
2024-03.
Hori K, Abe T, Abe N, Abe J, Okada K, Takahashi K, Harada S, Furumido J, Murai S, Kon M, Hashimoto K, Masumori N, Kakizaki H, Shinohara N. Gap analysis between trainees' subjective competencies and the competencies expected by instructors in urology: A need assessment survey in Japan. Int J Urol. 2024. [5Y-IF: 2.9]
2024-04.
Hosokawa C, Hotta K, Okamoto T, Cho Y, Hirose T, Iwahara N, Manabe A, Shinohara N. Prophylactic bilateral nephrectomy and preemptive kidney transplantation for Denys-Drash syndrome prior to development of kidney failure. Pediatr Nephrol. 2024;39(3):905-9. [5Y-IF: 3.4]
2024-05.
Hotta K, Miura M, Tanaka T, Tanabe T, Masumori N, Shinohara N. Surgical strategy for orthotopic kidney transplantation. Int J Urol. 2024. [5Y-IF: 2.9]
2024-06.
Kikuchi H, Abe T, Miyake M, Miyata H, Matsumoto R, Osawa T, Nishimura N, Fujimoto K, Inokuchi J, Yoneyama T, Tomida R, Numakura K, Matsushita Y, Matsumoto K, Sato T, Taoka R, Kobayashi T, Kojima T, Matsui Y, Nishiyama N, Kitamura H, Nishiyama H, Shinohara N. The impact of second transurethral resection on survival outcomes in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin therapy. Jpn J Clin Oncol. 2024;54(2):192-200. [5Y-IF: 2.6]
2024-07.
Kikuchi H, Maishi N, Yu L, Jia Z, Li C, Sato M, Takeda R, Ishizuka K, Hida Y, Shinohara N, Hida K. Low-dose metronomic cisplatin as an antiangiogenic and anti-inflammatory strategy for cancer. Br J Cancer. 2024;130(2):336-45. [5Y-IF: 8.4]
2024-08.
Kita Y, Otsuka H, Ito K, Hara T, Shimura S, Kawahara T, Kato M, Kanamaru S, Inoue K, Ito H, Igarashi A, Sazuka T, Takamatsu D, Hashimoto K, Abe T, Naito S, Matsui Y, Nishiyama H, Kitamura H, Kobayashi T. Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan. Int J Urol. 2024. [5Y-IF: 2.9]
2024-09.
Kusakabe N, Kamijo TC, Wada N, Chiba H, Shinohara N, Miyazato M. Effects of low-intensity extracorporeal shock wave therapy on lipopolysaccharide cystitis in a rat model of interstitial cystitis/bladder pain syndrome. Int Urol Nephrol. 2024;56(1):77-86. [5Y-IF: 2.2]
2024-10.
Matsuda A, Taoka R, Miki J, Saito R, Fukuokaya W, Hatakeyama S, Kawahara T, Fujii Y, Kato M, Sazuka T, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga K, Yamaguchi N, Iio H, Yasue K, Abe T, Nakanishi S, Matsumura M, Fujii M, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Matsui Y. Prognostic impact of histological discordance between transurethral resection and radical cystectomy. BJU Int. 2024. [5Y-IF: 4.5]
2024-11.
Shiota M, Takamatsu D, Matsui Y, Yokomizo A, Morizane S, Saito R, Miyake M, Tsutsumi M, Yamamoto Y, Tashiro K, Tomida R, Narita S, Edamura K, Yamaguchi T, Hashimoto K, Kato M, Kasahara T, Yoshino T, Akamatsu S, Kaneko T, Matsukawa A, Matsumoto R, Joraku A, Saito T, Kato T, Kato M, Enokida H, Sakamoto S, Terada N, Kanno H, Nishiyama N, Kimura T, Kitamura H, Eto M. Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy. Ann Surg Oncol. 2024. [5Y-IF: 4.4]
2024-12.
Shirai Y, Miura K, Ishizuka K, Ando T, Kanda S, Hashimoto J, Hamasaki Y, Hotta K, Ito N, Honda K, Tanabe K, Takano T, Hattori M. A multi-institutional study found a possible role of anti-nephrin antibodies in post-transplant focal segmental glomerulosclerosis recurrence. Kidney Int. 2024;105(3):608-17. [5Y-IF: 14.6]
2024-13.
Suzuki R, Kamiyama A, Ito H, Kawashiro K, Tomiyama T, Tamura T, Suzuki S, Yoshizumi T, Hotta K, Fukuhara T. The development of a rapid, high-throughput neutralization assay using a SARS-CoV-2 reporter. J Virol Methods. 2024;326:114894. [5Y-IF: 2.4]
2024-14.
Takada Y, Tanabe T, Sasaki H, Tsujimoto T, Hotta K, Okada K, Shiono Y, Minami K, Tanaka H, Harada H. Kidney donor age of 50 years or above is a risk factor for calcineurin inhibitor-induced nephrotoxicity. Clin Transplant. 2024;38(1):e15196. [5Y-IF: 2.4]
2024-15.
Uchishiba M, Yamamoto S, Takeda A, Arakaki R, Arata M, Noguchi H, Aoki H, Tamura K, Maeda T, Minato S, Nii M, Inui H, Kamada S, Kinouchi R, Yamamoto Y, Yoshida K, Yagi S, Kato T, Kaji T, Nishimura M, Ino K, Iwasa T. Progesterone treatment reduces food intake and body weight in ovariectomized female rats. Steroids. 2024;203:109367. [5Y-IF: 2.6]